

1 **The Effect of Diabetes Mellitus on the Pharmacokinetics of Tuberculosis Drugs**

2

3

4 **Authors:** Muge Cevik^{1*}, Ann Sturdy², Bart G.J. Dekkers³, Onno W. Akkerman^{4,5}, Stephen H.
5 Gillespie¹, Jan Willem C. Alffenaar^{6,7,8}

6

7

8 **Affiliations:**

9 1. Division of Infection and Global Health Research, School of Medicine, University of St Andrews,
10 UK

11 2. Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK

12 3. University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy
13 and Pharmacology, Groningen, the Netherlands

14 4. University of Groningen, University Medical Center Groningen, Department of Pulmonary
15 Diseases and Tuberculosis, Groningen, the Netherlands

16 5. University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord,
17 Haren, the Netherlands

18 6. The University of Sydney Institute for Infectious Diseases, Sydney, NSW, Australia.

19 7. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW,
20 Australia.

21 8. Westmead Hospital, Westmead, NSW, Australia

22

23 ***Corresponding author:**

24 Dr Muge Cevik

25 Division of Infection and Global Health Research,

26 School of Medicine, University of St Andrews, Fife, KY16 9TF

27 Telephone number: +447732800814

28 Email address: mc349@st-andrews.ac.uk

29

30 **This is the first systematic review to comprehensively examine the impact of DM on the**
31 **pharmacokinetics of TB drugs. While some studies showed lower plasma concentrations, we**
32 **observed significant heterogeneity; therefore, no recommendations can be made.**

33

34 **Abstract**

35

36 While pharmacokinetics (PK) of many drugs is known to be altered in individuals with diabetes
37 mellitus (DM), the effects of DM on the PK of anti-tuberculosis (TB) drugs remains poorly
38 understood.

39

40 We performed a systematic review through searches of major databases from 1946 to 6 July 2023.
41 The literature search identified 4173 potentially relevant articles. After reviewing the eligibility
42 criteria, 21 articles were included that assessed the PK of anti-TB drugs among patients with DM.

43

44 Most articles focused on first line TB drugs; we identified 16 studies assessing rifampicin PK, 9
45 studies on isoniazid, 8 on pyrazinamide and 3 assessing ethambutol. Only 2 studies reported on
46 second line anti-TB treatment. While some studies showed lower plasma concentrations of TB
47 medications among DM patients, this finding was not consistent. In addition, we observed high
48 variability in findings and significant heterogeneity among studies in terms of study design and
49 differences in demographics.

50

51 This review provides detailed overview of the limited evidence available regarding the PK of anti-
52 TB medications in patients with DM. However, due to significant heterogeneity between studies,
53 no conclusions could be made. Adequately designed PK studies using standardise methodologies
54 are urgently needed to make recommendations regarding drug dosing in patients affected both by
55 TB and DM.

56

57

58

59

60

61

62 Introduction

63

64 The global tuberculosis (TB) burden remains substantial, with more than 10 million people newly
65 diagnosed per year [1]. TB patients often have other co-morbidities that influence the disease
66 course and outcome. For instance, diabetes mellitus (DM) has been shown to increase the risk of
67 acquiring TB [2, 3] and progression to active disease [3, 4]. The coexistence of TB and DM (TB-DM)
68 has been associated with a 4-fold increased risk of treatment failure and 2-fold increased risk of
69 death [5-7]. In addition, TB-DM patients have been shown to have a higher bacterial burden,
70 delayed sputum culture conversion and a greater risk of developing drug resistance [6, 8].

71

72 Over the next 10 years, the prevalence of DM is estimated to double globally, affecting over 600
73 million individuals with a considerable increase in the African continent [9-11]. While DM has long
74 been acknowledged as an important risk factor for TB, the threat posed by the burden of these
75 two epidemics has recently been recognised [12, 13]. It is now considered a major global public
76 health concern by the World Health Organization (WHO) and a critical public health challenge in
77 low- and middle-income countries, with the WHO subsequently adopting a collaborative
78 framework for care and control of TB and DM [14].

79

80 While the burden of TB and DM co-disease is increasing rapidly, there is limited practical evidence
81 to underpin guidelines for TB-DM patient management, such as length of treatment, drug dosing
82 and use of therapeutic drug monitoring (TDM). Pharmacokinetics (PK) of anti-TB agents show
83 inter- and intra-patient variability and co-morbidities may further influence plasma
84 concentrations, as the PK of many other drugs are known to be altered in diabetic individuals [15].
85 DM may affect kidney function, gastric emptying and drug metabolism pathways [15, 16]. This
86 highlights the importance of understanding drug concentrations in TB-DM population as sub-
87 therapeutic concentrations may contribute to the treatment failure and acquired drug resistance
88 [17].

89

90 In this systematic review, we evaluated the available evidence on the PK of antituberculosis drugs
91 in diabetic individuals to provide in-depth analysis to guide patient management and identify
92 priorities for research.

93

94 Methods

95

96 ***Search Strategy***

97 We retrieved all original studies evaluating the effect of DM on the PK of all TB drugs
98 recommended by the WHO for the treatment of drug-sensitive (DS) and drug-resistant TB
99 including rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and/or ethambutol (EMB). We
100 systematically searched major databases; Medline, EMBASE, Web of Science and Scopus including
101 conference abstracts from 1946 to 6th of July 2023 using Medical Subject Headings (MeSH) terms
102 (Supplementary Material). We also manually screened the references of included original studies
103 to obtain additional studies. To identify unpublished studies, <http://clinicaltrials.gov> was searched.
104 This systematic review was conducted in accordance with the Preferred Reporting Items for
105 Systematic Reviews and Meta-Analyses (PRISMA) statement. The protocol was registered at
106 PROSPERO (CRD42022323566).

107

108 ***Study Selection***

109 Studies that reported PK of anti-TB medications among DM and non-DM participants were
110 included. No restrictions on language and publication date were applied. Studies in adult and
111 paediatric populations were included. General PK studies reporting a subgroup of DM participants
112 were not eligible unless they included detailed PK parameters for DM and non-DM participants.
113 Review articles, letters, case reports and case series with less than five participants and
114 correspondence were excluded, as were studies without PK data, drug interaction studies, and
115 non-human studies.

116

117 ***Data Extraction***

118 Two authors screened and retrieved articles according to the eligibility criteria and performed full
119 text review and final article selection. From each study, the following variables were extracted:
120 demographics of comparator group(s) and the DM group including age, weight, and sex, study
121 design, DM diagnosis, and DM medications. Dose, dosing interval, sampling points, AUC, peak drug
122 concentration (C_{max}), half-life ($t_{1/2}$), time to reach C_{max} (T_{max}), volume of distribution (V_d) and
123 clearance (CL) were extracted from the included articles if available and were stratified by group. If
124 these data were not reported, we also contacted the authors to request the data.

125

126 ***Risk of bias in included studies***

127 In the absence of available tools to assess risk of bias in PK studies, we assessed study quality and
128 risk of bias using the ROBINS-I tool for non-randomised studies of interventions, which was used to
129 assess PK studies in a recent publication [18, 19]. Any disagreements regarding grading of quality
130 were resolved through discussion with a third author.

131

132 **Analysis**

133 Narrative synthesis of the findings was conducted and reported according to the Synthesis
134 Without Meta-analysis (SWiM) guidelines [20]. Descriptive statistics was used to describe key
135 outcome measures. The data were found to be too heterogenous to permit further quantitative
136 synthesis.

137

138 **Results**

139 The systematic search identified 4173 potentially relevant articles. After removing duplicates,
140 3464 articles were retrieved for initial screening of which a total of 49 studies were included for
141 full text review. After reviewing the eligibility criteria, 21 articles were included that assessed the
142 PK of anti-TB medications among TB-DM patients [21-41]. Five included papers presented the
143 same data: in conference abstract [42-46] and then in published form [23, 29, 33, 36, 43]; we
144 included data from the published report. One study was only published as a conference abstract
145 and the authors were not able to share more data at the time of this review [47]. No relevant
146 unpublished studies were found on the ClinicalTrials.gov. The study selection process is recorded
147 in a PRISMA flow diagram (**Figure 1**).

148

149 **Rifampicin (Table 1)**

150 Of the 21 studies, 16 measured RIF plasma concentrations [21-23, 25, 27, 28, 30-36, 38-40],
151 majority of which were prospective PK studies except one retrospective study reporting results
152 based on routinely collected data [28]. RIF doses used were highly heterogeneous and are
153 presented in Table 1.

154

155 Out of 16 studies, 7 reported AUC values; three studies with intensive sampling (> 6 samples) [31,
156 32, 38] reported AUC₀₋₂₄ mg.h/L, three studies reported AUC₀₋₆ mg.h/L [21, 33, 36], and one
157 reported AUC₀₋₈ mg.h/L [27]. In one study, AUC₀₋₆ mg.h/L to RIF was significantly lower in patients
158 with TB-DM compared to those without DM) [33], another study found a lower trend AUC₀₋₂₄
159 mg.h/L in the DM group, but this was not statistically significant [32] and five studies found no

160 difference [21, 27, 31, 34, 38]. Of the three studies carrying out intensive sampling [31, 32, 38], no
161 significant difference was shown.

162

163 Out of 16 studies, 15 measured RIF peak concentrations (C_{max}); five demonstrated significantly
164 lower RIF peak concentrations among diabetic patients compared to non-diabetics [22, 28, 33, 39,
165 40] and ten studies showed no significant difference between diabetic and non-diabetic patients
166 [21, 25, 27, 30-32, 34-36, 38]. Mean absolute RIF C_{max} was below the recommended range (above
167 8 mg/L [48]) in diabetic and non-diabetic groups in the majority of studies, and within the
168 recommended range only in the 3 studies with intensive sampling [31, 32, 38].

169

170 Eight studies measured the time to reach C_{max} (T_{max}), which was longer in TB-DM participants in
171 three studies [31-33] (although without reaching statistical significance in one study [33]) and 3
172 studies found no significant difference [34, 36, 38]. In a study using population PK modelling,
173 absorption rate constant (k_a) was significantly increased and the volume of distribution (V_d) was
174 significantly increased in the DM [23], the authors inferring that the plasma concentrations would
175 therefore be lower in the DM group. Another study found no difference in k_a or V_d between the
176 TB and TB-DM groups in a 1 compartment model, but reduced clearance was observed and V_d was
177 significantly higher in the TB-DM group when V_d was normalized to total body weight [31].

178

179 Raised blood glucose was inversely correlated with the rifampicin AUC/C_{max} in four studies [31, 33,
180 39, 40], whereas three other studies found no association between HbA1c or fasting blood glucose
181 (FBG) and plasma concentrations [25, 32, 38]. Two studies found that body weight and plasma
182 concentrations were inversely correlated [22, 33].

183

184 **Isoniazid (Table 2)**

185 Nine studies assessed isoniazid (INH) PK [21, 22, 26-28, 30, 32, 35, 37]. Of these, one was based on
186 routinely collected retrospective data [28], four studies used 600 mg dosing 3 times per week [21,
187 27, 30, 35] and only 1 study sampled intensively [32]. Four studies assessed for NAT2 status using
188 different methods [26, 27, 32, 37]. We identified no studies with PK modelling.

189

190 Out of nine studies, four assessed the mean exposure; one AUC_{0-24} mg.h/L [32], two AUC_{0-6} mg.h/L
191 [21, 37] and one AUC_{0-8} mg.h/L [27]. Of these, two studies demonstrated significantly lower mean
192 exposure to INH [21, 32], although after adjustment for age, sex, and weight this difference

193 disappeared in one [21]. Two studies found no significant difference between the DM and non-DM
194 groups [27, 37]. Four studies found INH C_{max} to be significantly lower in the DM group [21, 22, 30,
195 32], though one reported no significant difference after adjustments for age, sex, and weight [21]
196 and the remaining 4 studies found no significant difference [26-28, 37]. One study with intensive
197 sampling found no significant difference [32]. Out of three studies assessing T_{max} , one found no
198 significant difference in INH T_{max} between the DM and non-DM group, and two studies did not
199 report comparative analysis [27, 37].

200

201 While one study reported concentrations to be negatively correlated with blood glucose [30], in
202 two studies INH C_{max}/AUC was not correlated with FBG or HbA1c [26, 32]. In one study INH
203 concentrations were inversely correlated with weight [22].

204

205 **Pyrazinamide (Table 3)**

206 Pyrazinamide PK was reviewed in eight studies [21, 22, 27, 29, 30, 32, 35, 38], all of which were
207 prospective PK studies. Patients in all studies except two were on 1500 mg PZA dosing, whilst one
208 study used 1600 mg for patients >50 kg and 1200 mg for patients <50 kg [32] and other used 20-30
209 mg/kg [29]. Out of eight, four papers reported mean exposure to PZA; two reporting AUC_{0-24}
210 mg.h/L [32, 38], one AUC_{0-8} mg.h/L [27] and one AUC_{0-6} mg.h/L [21]. Mean exposure to PZA was
211 significantly lower among DM participants in two studies [21, 27] and two studies with intensive
212 sampling reported no significant difference in AUC_{0-24} mg.h/L [32, 38]. Out of six studies reporting
213 C_{max} three reported significantly lower C_{max} among DM compared to non-DM participants [21, 27,
214 30], which remained significant after adjustments for age, sex, and weight [21] and three studies
215 reported no significant difference [22, 32, 38]. Three studies measured T_{max} and none reported a
216 statistically significant difference in T_{max} between the DM and non-DM TB groups.

217

218 No correlation between FBG and AUC/C_{max} was observed in two studies [32, 38] whereas one
219 study showed a negative correlation between plasma PZA concentrations and blood glucose [30].
220 In a population PK modelling study [29], increased apparent clearance was observed in TB-DM
221 patients, most significantly in the group with patients >70 years and AUC_{0-24} mg.h/L was decreased
222 in the DM group >70 years.

223

224 **Ethambutol (Table 4)**

225 Three included studies assessed the effect of DM on EMB PK [22, 32, 38]. Two reported AUC_{0-24}
226 mg.h/L and T_{max} [32, 38], all reported C_{max} . None of the studies reported statistically significant
227 difference in AUC, C_{max} , and T_{max} between the DM and non-DM groups. No correlation was seen
228 between FBG and AUC/C_{max} in two studies [32, 38]. We identified no studies with PK modelling.

229

230 **Other agents (Table 5)**

231 Two studies assessed the effect of DM on other agents; cycloserine [41], linezolid [41] and
232 moxifloxacin [24]. A retrospective cross-sectional study reviewing the cycloserine and linezolid
233 drug levels at 2 h post-dose in routine practice found that 55% of the samples had below the lower
234 limit of recommended cycloserine plasma concentrations and 17% had low linezolid
235 concentrations [41]. DM patients had a lower cycloserine exposure, although this was not
236 statistically significant, and there was no association between linezolid exposure and DM. In a
237 recent retrospective study evaluating moxifloxacin PK, AUC_{0-24h} was shown to be significantly
238 lower in patients with DM compared to age, sex and RIF matched TB patients without DM [24]. In
239 line, peak and trough concentrations were also reduced in DM patients. Although the drug
240 absorption, volume of distribution and T_{max} were comparable between TB-DM and TB patients,
241 moxifloxacin clearance was increased in TB-DM patients. Comparison of area under the unbound
242 drug concentration–time curve/minimal inhibitory concentration (MIC) ratio indicate that
243 exposure was already low in the majority of control patients, but none of the DM patients had
244 adequate exposure to moxifloxacin.

245

246 **Risk of bias assessment**

247 The risk of bias for each domain across all included studies is given in Supplementary material.
248 Prospective studies were the most common study design contributing to the review question,
249 except three studies where routinely collected TDM was used. While all studies have made a
250 comparative analysis between DM and non-DM population, all studies had moderate to serious
251 risk of bias in at least one domain. There was a high risk of bias for baseline confounders that may
252 have influenced the outcome result. For example, 11 out of 21 studies did not match DM and non-
253 DM groups according to age or sex. Non-adjustment of host factors may influence the plasma
254 concentrations, making it challenging to relate outcomes of the results to the effect of DM alone.
255 In addition, while most of the patients were on anti-diabetic medications, the degree of diabetic
256 control was not provided in the majority of studies. This highlights the challenges in studying the
257 PK of anti-TB medications in a patient population with complex background. Importantly, there

258 was also high risk of measurement bias in all prospective studies except three where intensive
259 sampling was conducted. As a result, evidence quality is influenced due to confounding and
260 imprecision, limiting our practice recommendations. Overall, the existing body of literature
261 examining PK of anti-TB medications among DM population is of medium quality.

262

263 **Discussion**

264

265 This systematic review provides a comprehensive account of the impact of DM on the PK of anti-
266 TB medications. Our findings suggest that the limited available evidence to date is highly variable.
267 While some studies showed lower plasma concentrations of TB medications among DM patients,
268 we observed high variability in findings and significant heterogeneity among studies including
269 study design and differences in demographics. Therefore, no recommendation can be made.

270

271 There may be several reasons to explain this heterogeneity. Firstly, there were significant
272 demographic differences including weight, age and DM definitions. Increased body surface area
273 distribution and delayed drug absorption due to DM related gastroparesis and changes in
274 expression of enzymes involved in metabolism [49, 50] are major factors that may contribute to
275 altered PK [15, 16]. DM patients had higher weight and/or BMI compared to nondiabetic patients
276 and some studies demonstrated a negative association between weight and plasma
277 concentrations. The only study that matched based on weight (within 5 kg) [38] found no
278 significant difference of RIF plasma concentrations between groups. However, matching weight is
279 unlikely to eliminate potential biases as DM participants continued to receive capped dosing
280 despite weight differences and were also generally older than non-DM controls.

281

282 Unclear DM definitions may also explain the variability. In many studies DM diagnosis was based
283 on self-report. This is specifically important as self-reporting may not be accurate and secondly, TB
284 could lead to stress-induced hyperglycaemia, which resolves after TB treatment [51]. Screening
285 DM at the time of TB diagnosis may result in some with transient hyperglycaemia being identified
286 as DM. Therefore, a standard measure of DM consistently defined and reported in PK studies in
287 line with the UNION criteria [52] would facilitate a better assessment of the plasma
288 concentrations [53]. Nevertheless, patients with transient hyperglycaemia may also be at risk of
289 lower plasma concentrations. For instance, in a study from Uganda, FPG was inversely correlated

290 with RIF AUC_{0-24h} [54]. In addition, quality of diabetes control or treatment was poorly reported in
291 most studies, which may have influenced the results.

292

293 PK sampling methodology and analysis varied widely. Studies with a single 2 hr sampling point
294 assume T_{max} to occur at 2 hrs (C_{max}). As T_{max} was longer for rifampicin in some studies, studies
295 without intensive sampling may not accurately capture the C_{max} . Notably, 3 studies with intensive
296 sampling [31, 32, 38] showed no differences in rifampicin or pyrazinamide C_{max} , but a significant
297 difference in isoniazid C_{max} (27). However, it is important to note T_{max} is highly variable for RIF in
298 general [55]

299

300 Particularly affecting the isoniazid studies, dosing differed markedly, with 4 out of 9 papers using
301 600 mg 3 times/week, which is no longer a recommended dosing, making the comparison
302 between the studies and the generalisation of the results more difficult. Only four out of 9 studies
303 made any assessment of NAT2 acetylator status. As this is recognised as a key variable in isoniazid
304 PK, this is likely to confound any other comparison of variables [56].

305

306 Plasma concentrations of TB medications may affect the clinical outcome. Zheng et al [57] showed
307 an association between plasma concentrations of first line anti-TB drugs and culture conversion
308 and clinical outcomes and Alfarisi et al. [21] demonstrated a positive association between time to
309 culture conversion and INH and RIF concentrations and negatively association with PZA levels in
310 DM patients. In another retrospective study, where all DM patients underwent TDM and dose
311 adjustment accordingly, time to culture conversion improved significantly greater among DM
312 patients with the post-intervention group that converted on average 19 days earlier [58].

313

314 We identified another systematic review assessing the impact of DM on the PK of rifampicin
315 among TB patients [59]. The review included studies published up until September 2020 and
316 identified seven studies from which pooled estimates were calculated. The same authors updated
317 their systematic review including studies with C_{max} at 2hr [60], and identified 17 studies reporting
318 RIF plasma concentrations. Our review considers studies published up to July 2023 with a
319 comprehensive systematic search; therefore, we were able to identify 16 papers assessing the PK
320 of RIF.

321

322 To our knowledge, this is the first review to comprehensively examine the impact of DM on the PK
323 of TB drugs. Our study has limitations. Firstly, we identified a limited number of PK studies among
324 DM patients despite a comprehensive literature search. Secondly, due to the substantial study
325 heterogeneity we were unable to pool data. Finally, we did not include general PK studies
326 reporting on TB-DM patients as a subgroup as detailed and comparative PK parameters for DM vs
327 non-DM patient populations weren't available.

328

329 This review provides detailed understanding about the evidence available so far on PK of anti-TB
330 drugs in patients with DM. There is some evidence that PK, especially among DM patients, may
331 have clinical relevance in terms of MIC and culture conversion. However, significant heterogeneity
332 observed in studies and the scarcity of data on clinical outcomes, it is challenging to make
333 recommendations about dosing in the TB-DM population. Given the relationship of delayed
334 culture conversion and relapse, clinical outcomes should be explored in future PK studies. In order
335 to achieve definitive answers for PK in DM population, we recommend important considerations
336 as in **Table 6**. Until we have further information to guide the management of TB-DM patients,
337 TDM and dose adjustment may be beneficial in patients with DM.

338

339 **Acknowledgements**

340 This work was supported by the Chief Scientist Office (CAF/20/03) and British Infection Association
341 (Grant/2022/SPG/MC) received by MC.

342

343 **Author contributions**

344 MC and SHG conceptualized the scope of the review. MC and AS pulled the data from selected
345 papers. All authors contributed to the final version of the manuscript and approved it for
346 publication.

347

348 **Declaration of Interests**

349 No conflict of interests reported.

350

351 **References:**

352


- 353 1. WHO. World Health Organization, Global tuberculosis report 2022
354 . Available at: <https://www.who.int/publications/i/item/9789240061729>.
- 355 2. Koesoemadinata RC, McAllister SM, Soetedjo NNM, et al. Latent TB infection and
356 pulmonary TB disease among patients with diabetes mellitus in Bandung, Indonesia. *Trans*
357 *R Soc Trop Med Hyg* **2017**; 111(2): 81-9.
- 358 3. Foe-Essomba JR, Kenmoe S, Tchatchouang S, et al. Diabetes mellitus and tuberculosis, a
359 systematic review and meta-analysis with sensitivity analysis for studies comparable for
360 confounders. *PLoS One* **2021**; 16(12): e0261246.
- 361 4. Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes
362 mellitus and active tuberculosis: A systematic review and meta-analysis. *PLoS One* **2017**;
363 12(11): e0187967.
- 364 5. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment
365 outcomes: a systematic review. *BMC Med* **2011**; 9: 81.
- 366 6. Salindri AD, Kipiani M, Kempker RR, et al. Diabetes Reduces the Rate of Sputum Culture
367 Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis. *Open*
368 *Forum Infect Dis* **2016**; 3(3): ofw126.
- 369 7. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on
370 tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *Int J*
371 *Tuberc Lung Dis* **2019**; 23(7): 783-96.
- 372 8. Dong Z, Shi J, Dorhoi A, et al. Hemostasis and Lipoprotein Indices Signify Exacerbated
373 Lung Injury in TB With Diabetes Comorbidity. *Chest* **2018**; 153(5): 1187-200.
- 374 9. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes
375 prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* **2018**; 138: 271-81.
- 376 10. Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751
377 population-based studies with 4.4 million participants. *Lancet* **2016**; 387(10027): 1513-30.
- 378 11. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active
379 tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with
380 tuberculosis. *Lancet Glob Health* **2019**; 7(4): e448-e60.
- 381 12. Pan SC, Ku CC, Kao D, Ezzati M, Fang CT, Lin HH. Effect of diabetes on tuberculosis
382 control in 13 countries with high tuberculosis: a modelling study. *Lancet Diabetes*
383 *Endocrinol* **2015**; 3(5): 323-30.
- 384 13. Harries AD, Kumar AM, Satyanarayana S, et al. Addressing diabetes mellitus as part of the
385 strategy for ending TB. *Trans R Soc Trop Med Hyg* **2016**; 110(3): 173-9.
- 386 14. WHO. Integrated care for tuberculosis (TB) and diabetes mellitus (DM) comorbidity in
387 Asian countries: health system challenges and opportunities
388 , **2022**.
- 389 15. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and
390 pharmacodynamic properties of drugs. *Clin Pharmacokinet* **2012**; 51(8): 481-99.
- 391 16. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics
392 and pharmacodynamics in humans. *Clin Pharmacokinet* **1991**; 20(6): 477-90.
- 393 17. Gillespie SH. Evolution of drug resistance in *Mycobacterium tuberculosis*: clinical and
394 molecular perspective. *Antimicrob Agents Chemother* **2002**; 46(2): 267-74.
- 395 18. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in
396 non-randomised studies of interventions. *BMJ* **2016**; 355: i4919.
- 397 19. Gafar F, Wasmann RE, McIlleron HM, et al. Global estimates and determinants of
398 antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and
399 individual patient data meta-analysis. *Eur Respir J* **2023**; 61(3).
- 400 20. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in
401 systematic reviews: reporting guideline. *BMJ* **2020**; 368: l6890.

- 402 21. Alfarisi O, Mave V, Gaikwad S, et al. Effect of Diabetes Mellitus on the Pharmacokinetics
403 and Pharmacodynamics of Tuberculosis Treatment. *Antimicrob Agents Chemother* **2018**;
404 62(11): 11.
- 405 22. Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin are
406 decreased in adult pulmonary tuberculosis patients with diabetes mellitus. *Antimicrob*
407 *Agents Chemother* **2013**; 57(11): 5740-2.
- 408 23. Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the population
409 pharmacokinetics of rifampin in tuberculosis patients. *Tuberculosis (Edinb)* **2015**; 95(1): 54-
410 9.
- 411 24. Dekkers BGJ, Bolhuis MS, Beek LT, et al. Reduced moxifloxacin exposure in patients with
412 tuberculosis and diabetes. *European Respiratory Journal* **2019**; 54(3) (no pagination).
- 413 25. Fonseca AAD, Pinto ACG, Paixao TPD, Alberio CAA, Vieira JLF. Can diabetes mellitus
414 modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
415 *Brazilian Journal of Infectious Diseases* **2020**; 24(4): 352-5.
- 416 26. Galvao FES, Fonseca AAD, Pinto ACG, da Paixao TP, Alberio CAA, Vieira JLF. No
417 significant influence of diabetic mellitus on isoniazid plasma levels in patients under
418 treatment for tuberculosis. *Infectious Diseases* **2020**; 52(8): 577-80.
- 419 27. Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of thrice-
420 weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. *Int J*
421 *Tuberc Lung Dis* **2016**; 20(9): 1236-41.
- 422 28. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response
423 to tuberculosis treatment in a state control program, Virginia, USA. *Emerg Infect Dis* **2010**;
424 16(10): 1546-53.
- 425 29. Kim R, Jayanti RP, Kim HK, et al. Development of a population pharmacokinetic model of
426 pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on
427 clearance. *Front Pharmacol* **2023**; 14 (no pagination): 1116226.
- 428 30. Kumar AK, Chandrasekaran V, Kannan T, et al. Anti-tuberculosis drug concentrations in
429 tuberculosis patients with and without diabetes mellitus. *Eur J Clin Pharmacol* **2017**; 73(1):
430 65-70.
- 431 31. Medellin-Garibay SE, Cortez-Espinosa N, Milan-Segovia RC, et al. Clinical
432 Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus:
433 Association with Biochemical and Immunological Parameters. *Antimicrob Agents*
434 *Chemother* **2015**; 59(12): 7707-14.
- 435 32. Mtabho CM, Semvua HH, van den Boogaard J, et al. Effect of diabetes mellitus on TB drug
436 concentrations in Tanzanian patients. *J Antimicrob Chemother* **2019**; 74(12): 3537-45.
- 437 33. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in
438 patients with tuberculosis and type 2 diabetes. *Clin Infect Dis* **2006**; 43(7): 848-54.
- 439 34. Perea-Jacobo R, Muniz-Salazar R, Laniado-Laborin R, Cabello-Pasini A, Zenteno-Cuevas
440 R, Ochoa-Teran A. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a
441 pilot study from Baja California, Mexico. *Int J Tuberc Lung Dis* **2019**; 23(9): 1012-6.
- 442 35. Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic rifampicin
443 concentration is associated with unfavorable tuberculosis treatment outcomes. *Clin Infect*
444 *Dis* **2020**; 70(7): 1463-70.
- 445 36. Requena-Mendez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in Peruvian
446 tuberculosis patients with and without comorbid diabetes or HIV. *Antimicrob Agents*
447 *Chemother* **2012**; 56(5): 2357-63.
- 448 37. Requena-Mendez A, Davies G, Waterhouse D, et al. Effects of dosage, comorbidities, and
449 food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. *Antimicrob Agents*
450 *Chemother* **2014**; 58(12): 7164-70.
- 451 38. Ruslami R, Nijland HM, Adhiarta IG, et al. Pharmacokinetics of antituberculosis drugs in
452 pulmonary tuberculosis patients with type 2 diabetes. *Antimicrob Agents Chemother* **2010**;
453 54(3): 1068-74.

- 454 39. Samuel Gideon George P, Saranya P. Effect of patient-specific variables on rifampicin peak
455 serum concentration. *Drug Invention Today* **2018**; 10(3): 290-6.
- 456 40. Saranya P, Parthasarathy V, Hariprasad B, Shobha Rani H. Effect of diabetes mellitus on
457 rifampicin peak serum concentration. *International Journal of Pharmacy and Pharmaceutical*
458 *Sciences* **2016**; 8(10): 149-52.
- 459 41. Zhu H, Guo SC, Liu ZQ, et al. Therapeutic drug monitoring of cycloserine and linezolid
460 during anti-tuberculosis treatment in Beijing, China. *Int J Tuberc Lung Dis* **2018**; 22(8):
461 931-6.
- 462 42. Chang MJ, Shin W, Song J, et al. The pharmacokinetics of four standard anti-tuberculosis
463 drugs in tuberculosis patients with diabetes mellitus. *Respirology* **2009**; 3): A231.
- 464 43. Mtabho C, Semvua H, Kibiki G, Tostmann A, Aarnoutse R. The effect of diabetes mellitus
465 on the pharmacokinetics of tuberculosis drugs in Tanzanian patients. *Tropical Medicine and*
466 *International Health* **2015**; 1): 23.
- 467 44. Nijland H, Ruslami R, Stalenhoef J, et al. Exposure to rifampicin is reduced by 53% in
468 tuberculosis patients with Diabetes Mellitus. *Br J Clin Pharmacol* **2006**; 62(6): 730-.
- 469 45. Mendez AR, Moore DAJ, Davies G. Improving management of TB in the tropics
470 Rifampicin pharmacokinetics in peruvian tuberculosis patients with and without co-morbid
471 diabetes or HIV. *Tropical Medicine and International Health* **2011**; 1): 62.
- 472 46. Kim R, Jayanti R, Jang T, et al. Development of Population Pharm Aco Kin Etics Model of
473 Pyrazinamide and Optimal Dose Recommendation for Elderly with Diabetes Mellitus in
474 Korean Tuberculosis Patients. *Clinical Pharmacology and Therapeutics* **2023**;
475 113(Supplement 1)(S1): S94.
- 476 47. Christopher DJ, Jedidiah D, Isaac B, Mathew B, Winston B. Anti-tubercular drug
477 concentrations in pulmonary tuberculosis patients-diabetic vs non-diabetic groups. *European*
478 *Respiratory Journal Conference: 29th International Congress of the European Respiratory*
479 *Society, ERS Madrid Spain* **2019**; 54(Supplement 63).
- 480 48. Peloquin CA, Velasquez GE, Lecca L, et al. Pharmacokinetic Evidence from the HIRIF
481 Trial To Support Increased Doses of Rifampin for Tuberculosis. *Antimicrob Agents*
482 *Chemother* **2017**; 61(8).
- 483 49. Kuppusamy UR, Indran M, Rokiah P. Glycaemic control in relation to xanthine oxidase and
484 antioxidant indices in Malaysian Type 2 diabetes patients. *Diabet Med* **2005**; 22(10): 1343-
485 6.
- 486 50. Dash RP, Ellendula B, Agarwal M, Nivsarkar M. Increased intestinal P-glycoprotein
487 expression and activity with progression of diabetes and its modulation by epigallocatechin-
488 3-gallate: Evidence from pharmacokinetic studies. *Eur J Pharmacol* **2015**; 767: 67-76.
- 489 51. Ugarte-Gil C, Alisjahbana B, Ronacher K, et al. Diabetes mellitus among pulmonary
490 tuberculosis patients from four TB-endemic countries: the TANDEM study. *Clin Infect Dis*
491 **2019**.
- 492 52. Lin Yan ADH, Ajay M V Kumar, Julia A Critchley, Reinout van Crevel, Philip Owiti, Riitta
493 A Dlodlo, Anders Dejgaard. MANAGEMENT OF DIABETES MELLITUS-
494 TUBERCULOSIS - A GUIDE TO THE ESSENTIAL PRACTICE
495 , **2019**.
- 496 53. LinY HAD, Kumar A MV, Critchley J A, van Crevel R, Owiti P, Dlodlo R A, Dejgaard A.
497 Management of diabetes mellitus-tuberculosis: a guide to the essential practice. *International*
498 *Union Against Tuberculosis and Lung Disease* **2019**.
- 499 54. Wyrsh F, von Braun A, Sekaggya-Wiltshire C, et al. Hyperglycaemia and
500 pharmacokinetics of rifampicin/isoniazid among TB-HIV co-infected patients in Kampala,
501 Uganda. *Int J Tuberc Lung Dis* **2020**; 24(12): 1234-40.
- 502 55. Sturkenboom MG, Mulder LW, de Jager A, et al. Pharmacokinetic Modeling and Optimal
503 Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with
504 Tuberculosis. *Antimicrob Agents Chemother* **2015**; 59(8): 4907-13.

- 505 56. Hong BL, D'Cunha R, Li P, et al. A Systematic Review and Meta-analysis of Isoniazid
506 Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. *Clin Ther* **2020**;
507 42(11): e220-e41.
- 508 57. Zheng X, Bao Z, Forsman LD, et al. Drug Exposure and Minimum Inhibitory Concentration
509 Predict Pulmonary Tuberculosis Treatment Response. *Clin Infect Dis* **2021**; 73(9): e3520-
510 e8.
- 511 58. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for
512 diabetes related tuberculosis associate with hastened sputum microbiological clearance in
513 Virginia, USA. *BMC Infect Dis* **2017**; 17(1): 125.
- 514 59. Metwally AS, El-Sheikh SMA, Galal AAA. The impact of diabetes mellitus on the
515 pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-
516 analysis study. *Diabetes Metab Syndr* **2022**; 16(2): 102410.
- 517 60. El-Sheikh SMA, Metwally AS, Galal AAA. Impact of diabetes mellitus on rifampicin's
518 plasma concentration and bioavailability in patients with tuberculosis: A systematic review
519 and meta-analysis study. *Therapie* **2023**; 78(3): 313-24.
- 520

Figure 1. Flowchart describing study selection



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Rifampicin

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.29.23294656>; this version posted August 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Study	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C _{max}	AUC	T _{max} (Hrs)	DM Control	DM Treatment	Other PK
Nijland 2006	Indonesia	Prospective PK	17/34	Matched Median 50 (DM) v 48 (nonDM)	Matched (59% male)	Significantly higher in DM group (median kg 55.6 versus 46.2 p0.01)	2/4/6 hr	Continuation	450	Rifampicin 450mg Isoniazid 300mg 3x week	Pulmonary Microbiologically confirmed	Known Screening via FBGx2	mg/L Significantly lower in DM group Mean 3.49 (2.1-5.6) DM v 5.6 (5.6 - 10.1) nonDM p0.0003	0-6h mg x h/L Significantly lower in DM group 12.3 (8.0-24.2) DM v 25.9 (21.4-40.2) nonDM p0.003	T _{max} longer in DM group, but not significant Median 4 (2-6 range) DM v 2 (2-4) nonDM, p0.52	Median HbA1c 9.85% Median FBG 9.3mmol/L	71% on oral antidiabetic meds. No metformin or insulin	Body weight, raised FBG, DM inversely correlated with AUC/C _{max} on MV analysis
Ruslami 2010	Indonesia	Prospective PK	17/34	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0.00	Matched (42% male)	Matched (within 5kg) (mean 47.3kg both groups)	Intensive	Intensive	450	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg Daily	Pulmonary	Known (60%) Screening via WHO criteria (40%)	mg/L No difference Mean 10.5 (12.3 95% CI) DM v 9.6 (8.4-11.1) nonDM p0.0003	0-24 mg x h/L No difference Mean 49.0 (40.9-58.7) DM v 50.6 (42.9-59.8) nonDM p0.81	No difference Median 2 (0.5-4 range) DM v 2.5 (1-4) nonDM p0.28	Mean HbA1c 11.1% Median FBG 16.6mmol/L	None	No correlation between FBG and AUC/C _{max} . 10 DM cases treated with insulin to achieve glycaemic control, with PK repeated 6 weeks later – non-significant change in AUC/other PK Has further detailed PK if needed
Heysell 2010	USA	Retrospective cohort using routinely collected data TDM carried out for patients defined as 'slow to respond'	17/42	36% 18-39, 36% 40-54, 28% >65 Total group – no breakdown for DM	67% male of total group (nil breakdown for DM)	Unknown	2 hr	Unknown	Unknown	Rifampicin Isoniazid Pyrazinamide Ethambutol Some daily, some 2x week R/H	Pulmonary or extrapulmonary Microbiologically confirmed	Unknown	C _{max} defined as sample Normal range 10-20 µg/mL DM significantly associated with low 2hr R Low R level DM, 41% non-normal R level 20% DM, 80% nonDM. OR (1.4-23.1 95% CI) p0.01	NA	NA	Unknown	Unknown	No quantitative C _{max} data available comparing DM and non-DM groups
Requena-Mendez 2012	Peru	Prospective comparing DM group, HIV group and non-DM/HIV group	26/105 (29 HIV, 50 nonDM/nonHIV)	Significantly higher in DM group (51.3 versus 31.1 nonDM/HIV)	65.4% male DM group, 48.0% nonDM/HIV	BMI reported rather than weight. Significantly higher in DM group (27.5 versus 23.3 nonDM/nonHIV group)	2hr, 6hrs	1 time point for each case, 61/105 intensive, 44/105 continuous (50% each in DM group)	10mg/kg to maximum 600	Rest of regimen not stated x6/week dosing in intensive, x2/week in continuation	87% pulmonary, 77/105 microbiologically confirmed	Known	mg/L Cmax taken at highest of 2hr 6hr sample No difference in DM group Cmax mean at 2hrs – 5.1 DM non-DM (p0.9) Cmax mean at 6hrs – 3.4 DM non-DM (p0.2) No association between Cmax and DM on MVA analysis	NA	6hrs rather than 2hrs in 62.2% cases (no association with DM)	Median HbA1c 8.3%	Unknown	Majority of patients with concentrations lower than therapeutic range – no particular association with DM.
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116)	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr4	Intensive at 14 and 30 days after starting treatment	600	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only Significantly lower in DM group at D14 and D30 (day 14 mean 5.1 µg/mL nonDM, 2.9 DM, p<0.05, day 30 mean 5.4 nonDM versus 3.2 DM, p<0.05)	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	Concentration inversely correlated with weight
Chang 2015	Korea	Prospective with analysis using population PK	21/54	Median 55 (20-92 range) for whole group, no breakdown of DM group	63% male whole group, no breakdown DM group	Mean 53.96kg whole group, no breakdown DM group	1,2,4,6hrs	Intensive	10 mg/kg (up to 450 mg or 600 mg)	Rifampicin 10 mg/kg (max 450 mg or 600 mg) Isoniazid 5 mg/kg (max 300 mg or 400 mg) Pyrazinamide 15-30 mg/kg (max 1500 mg) Ethambutol 15-20 mg/kg (max 800 mg, 1000 mg or 1200 mg) Daily	Combination clinical/radiological/microbiological	FBG >126 mg/dl or post-prandial glucose levels >200 mg/dl	NA	NA	Mean fasting blood glucose 154.8 mg/dL	Unknown	ka (absorption rate constant) significantly increased in DM group (2.81 hr ⁻¹ , versus 1.33, p<0.05) Vd (volume of distribution) significantly increased in DM group (76.3L versus 46.1, p<0.05) Infer from increased Vd in DM group, that plasma concentration would be lower in DM group	
Medellin-Garibay 2015	Mexico	Prospective intensive PK with additional immunology study	24/48	DM group older Median 52.2 versus 37.3	Matched	Higher median BMI in DM group (23.3 versus 21.6)	Intensive	Intensive	450 if <50kg 600 if >50kg	Rifater 450/600 Rifampicin 225/300 Isoniazid 1200/1600 Pyrazinamide (Weight </>50kg) per tablet	Microbiologically confirmed	Known or screened: fasting glucose >126 mg/dl or HbA1c >6.5%	Mg/L No significant difference Median Cmax DM group 12.10 ± 5.1 versus 11.41 ± 3.8, p0.44	AUC 0-24 (mg.hr.L) No significant difference Median DM group 97.52 ± 36.7 versus 82.60 ± 35.5, p0.17	Significantly increased in Dm group Median DM 2.98 ± 1.9 versus 2.32 ± 1.4	Median HbA1c 9.02%	63% on treatment	No difference in ka or VD between TB and TBDM group in 1 compartment model, but reduced clearance in Dm group Tlag significantly increased in Dm group Tlag positively correlated with increased HbA1c, Cmax negatively correlated with increased fasting glucose
Hemant Kumar 2016	India	Prospective PK to assess x3 weekly regimen, with	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	450 (600 if >60kg)	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200	Pulmonary or EP	Known or random blood glucose >200 µg/mL	µg/mL No significant difference Median DM 5.7	AUC 0-8 µg/ml.hr No significant difference Median DM 27.6	2hrs for whole group – no analysis comparing DM	Unknown	Unknown	DM not significant as a factor on multivariate analysis (Cmax and AUC)

Rifampicin

		DM as one covariate								+/- Streptomycin 750 3x weekly			(4.2 – 7.1) versus nonDM 4.9 (3.6-6.6), p0.24	(22.0-37.3) versus nonDM 27.9 (20.0-32.7), p0.35	to nonDM				
Saranya 2016	India	Prospective PK	20/45	DM group older Mean 46.6 v 42.4	68.9% male (no breakdown of DM group)	Weight not significantly different between DM and nonDM (p=0.544), 89.9% total <50kg	2hr	Not specified	Not specified	Not specified	Pulmonary	Unknown	C2hr only Significantly lower in DM group No absolute numbers given	NA	NA	Unknown	83% on insulin and metformin	Cmax negatively correlated with RBG	
Kumar 2017	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in DM group (73.5% versus 65.7, p0.002)	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	450 (600 if >60kg)	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 µg/mL (16% new)	µg/mL C2hr only No significant difference Median DM (0.6-5), nonDM (0.7-4.9)	NA	NA	Median random blood glucose 263.5 mg/dL	Majority of diabetes group on treatment		
Alfarisi 2018	India	Prospective cohort, both PK and PK-PD	101/243	DM significantly older (median age 48 versus 26, p<0.001)	Significantly more men in DM group (77% versus 61%, p<0.001)	Weight significantly increased in DM group (50.8kg versus 45kg, p<0.001)	0.5,2,6hrs	x1 intensive x1 continuation	450	Rifampicin 450 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 3x weekly Rif/so alone in continuation (3x weekly)	Pulmonary	Known or HbA1c >6.5%, fasting blood glucose concentration >126 mg/dl, or random blood glucose >200 mg/dl	µg/mL No significant difference Intensive: mean DM 3.63, nonDM 4.32, p0.17 Continuation: mean DM 3.88, nonDM 2.98, p0.17	AUC0-6 µg.hr/ml No significant difference Intensive: mean DM 12.19, nonDM 15.34, p0.11 Continuation: mean DM 14.56, nonDM 11.13 p0.14	NA	NA	Median HbA1c at baseline 8.9%	44.6% on metformin	
Samuel Gideon George 2018	India	Prospective PK	24/60	Mean 44.78yrs (no breakdown of DM group)	71.7% male (no breakdown of DM group)	Weight significantly increased in DM group (mean 50.87kg versus 42.36kg, p<0.001)	2hr	Intensive	450/600 (?weight cut off)	Rifampicin 450/600 Isoniazid Pyrazinamide Ethambutol 3x weekly Doses not specified	Pulmonary, smear and radiologically positive	Not stated	µg/mL C2hr only Significantly lower in DM group Mean DM 4.0 (SD 0.4), nonDM 4.7 (SD 0.4), p0.02	NA	NA	Unknown	Unknown	Cmax negatively correlated with RBG	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	600 (>50kg), 450 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radiological/microbiological	Known or fasting glucose >7mmol/L	mg/L No significant difference Mean DM 20.7, nonDM (5.9-14.8) p0.001	AUC0-24 mg.h/L Trend to lower in DM group but not significant Mean DM 29.9 (6.4-69.7), nonDM 39.9 (27.4-68.3), p0.052	Significantly longer in DM Median DM 2.1hrs versus 1.1hrs, p0.02	Median HbA1c 111mmol/mol	84% on oral medications	Cmax/AUC not associated with fasting glucose or HbA1c results	
Perea-Jacobo 2019	Mexico	Prospective PK	16/30	DM significantly older (mean age 46.6yrs versus 37.2, p0.018)	No difference between groups (75% male DM group versus 71%)	No difference in BMI (Mean DM 23.6 versus 22.3, p0.323)	2.5,6,24hrs	Intensive	600	Rifampicin 600 Isoniazid 300 Pyrazinamide 1600 Ethambutol 1200 Daily	Pulmonary and extrapulm, micro confirmed	Fasting glucose >126 mg/dl or HbA1c >6.5%	µg/mL No significant difference Mean DM 4.1, nonDM 5.0, p0.37	AUC0-6 mg.h/l No significant difference Mean DM 14.3 ± 7.5, nonDM 21.6 ± 16.3, p0.13	No significant difference Mean DM 5.6 ± 7.3, nonDM 4.0 ± 6.1, p0.50	Unknown	88% on treatment		
Fonseca 2020	Brazil	Prospective PK	26/62	No difference (median 39yrs versus 44)	100%	Weight significantly higher in DM group (Median 64kg versus 54kg)	2hrs	Intensive/ Continuation (D61)	600	Rifampicin 600 Isoniazid 300 Pyrazinamide 1600 Ethambutol 1100 Daily R/H only in continuation	Pulmonary, clinical, radio, micro	Fasting glucose >126 mg/dl or HbA1c >6.5%	µg/mL C2hr only No significant difference Median DM 6.8-9 range), nonDM 6.16 (3.0-14.2), p0.37	NA	NA	Median HbA1c 9.6%	15% on treatment	No association between concentrations and HbA1c or FBG	
Ramachandran 2020	India	Prospective PK, specifically looking at association between C _{2hr} and outcomes.	113/404	Median age 40, no breakdown of DM group	64, no breakdown DM group	BMI Median 17.8, no breakdown DM group	2hrs	Intensive and Continuation	450/600 if >60kg	R 450/600 H 600 Z 1500 E 1200 3x weekly CP: R/H	Pulmonary	Known or HbA1c >6.5%, or RBG >200 mg/dl	µg/mL C _{2hr} No significant difference I: Median 3.64 (1.78-6.58 IQR) v 3.47 (1.33-6.40), p0.49 C: 5.91 (2.13-9.51) v 4.41 (1.65-7.46), p0.07	NA	NA	Unknown	Unknown		

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.29.23294656>; this version posted August 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Pyrazinamide

Study	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C _{max}	AUC	T _{max} (Hrs)	DM Control	DM Treatment	Other PK
Ruslami 2010	Indonesia	Prospective PK	18/36	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0.00	Matched (42% male)	Matched (mean 47.3kg both groups)	Intensive	Intensive	1500	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg	Pulmonary	Known (60%) Screening via WHO criteria (40%)	mg/L No difference Mean 45.5 (41.6-49.3 95% CI) DM v 47.0 (44.1-50.1) nonDM p0.47	0-24 mg x h/L No difference Mean 409 (369-455) DM v 468 (422-519) nonDM p0.07	No difference Median 1 (0.5-4 range) DM v 1.5 (0.5-6) nonDM p0.61	Mean HbA1c 11.1% Median FBG 16.6mmol/L	None	No correlation between FBG and AUC/C _{max} 10 DM cases treated with insulin to achieve glycaemic control, with PK repeated 6 weeks later – non significant change in AUC/other PK
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116)	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	1500	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only No significant difference at D1 and D30 (day 1 mean 23.4 µg/ml nonDM, 25.9 DM, p>0.05, day 30 27.9 nonDM versus 23.4 DM, p>0.05)	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	
Hemant Kumar 2016	India	Prospective PK to assess x3 weekly regimen, with DM as one covariate	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	1500	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known of random blood glucose >200 µg/mL	µg/mL Significantly lower DM group Median DM 36 (28.8 – 41.6) versus nonDM 40.5 (34.5-45.0), p0.007. DM non-significant on multivariate analysis	AUC 0-8 µg/ml.hr Significantly lower in DM group Median DM 192.6 (158.4-230.4) versus nonDM 232.3 (206.0-256.1-61.1), p<0.001 DM non-significant on multivariate analysis	2hrs for whole group – no analysis comparing DM to nonDM	Unknown	Unknown	
Kumar 2017	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in Dm group (73.5% versus 65.7, p0.002)	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	1500	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 µg/mL (16% new)	µg/mL C2hr only DM significantly lower Median DM 31 (22.3-38.0), nonDM 34.1 (24.6-42.7), p<0.001 DM remained significant independent factor on linear regression	NA	NA	Median random blood glucose 263.5 mg/dL	Majority of diabetes group on treatment	Concentration negatively correlated with blood glucose
Alfarisi 2018	India	Prospective cohort, both PK and PK-PD	101/243	DM significantly older (median age 48 versus 26, p<0.001)	Significantly more men in DM group (77% versus 61%, p<0.001)	Weight significantly increased in DM group (50.8kg versus 45kg, p<0.001)	0.5, 2,6hrs	x1 intensive x1 continuation	1500	Rifampicin 450 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 3x weekly Rif/iso alone in continuation (3x weekly)	Pulmonary	Known or HbA1c >6.5%, fasting blood glucose concentration >126 mg/dl, or random blood glucose >200 mg/dl	µg/mL Significantly lower DM group, remaining significant on adjustment Mean DM 21.59, nonDM 32.75, p0.002, adjusted p0.03	AUC0-6 µg.hr/ml Significantly lower in DM group, remaining significant on adjustment Mean DM 80.89, nonDM 128.43, p<0.001, adjusted p0.003		Median HbA1c at baseline 8.9%	44.6% on metformin	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	1600(>50kg), 1200 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radiological/microbiological	Known or fasting glucose >7mmol/L	mg/L No significant difference Mean DM 34.5 (21.4-46.2), nonDM 38.2 (29.0-50.8) p0.09	AUC0-24 mg.h/L No significant difference Mean DM 290 (123-420), nonDM 344 (209-609), p0.08	No significant difference Median DM 1.1hrs versus 1.1hrs, p0.25	Median HbA1c 111mmol/mol	84% on oral medications	Cmax/AUC not associated with fasting glucose or HbA1c results
Ramachandran 2020	India	Prospective PK, specifically looking at association between C _{2hr} and outcomes.	113/404	Median age 40, no breakdown of DM group	64, no breakdown DM group	BMI Median 17.8, no breakdown DM group	2hrs	Intensive	1500	R 450/600 H 600 Z 1500 E 1200 3x weekly CP: R/H	Pulmonary	Known or HbA1c >6.5%, or RBG >200 mg/dl	µg/mL C _{2hr} No significant difference Median 34.95 (25.03-43.42 IQR) v 37.49 (28.26-46.17), p0.08	NA	NA	Unknown	Unknown	
Kim 2023	Korea	Prospective with population PK analysis	55/613	Median age 54yrs, no breakdown DM group	67% male, no breakdown DM group	Weight Median 60.8kg, no breakdown DM group	Random 1-2 samples for each patient between 0-24hrs	Intensive	20-30mg/kg	Not specified	Microbiologically confirmed pulmonary	Not specified	NA	NA	NA	Unknown	Unknown	Increased apparent clearance in DM, most significantly in >70yrs group. Decreased AUC 0-24 in >70yrs DM group.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.29.23294656>; this version posted August 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Isoniazid

Study	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C _{max}	AUC	T _{max} (Hrs)	DM Control	DM Treatment	Other PK
Heysell 2010	USA	Retrospective cohort using routinely collected data TDM carried out for patients defined as 'slow to respond'	16/39	31% 18-39, 38% 40-54, 31% >65 Total group – no breakdown for DM	67% male of total group (nil breakdown for DM)	Unknown	2 hr	Unknown	Unknown	Rifampicin Isoniazid Pyrazinamide Ethambutol Some daily, some 2x week R/H	Pulmonary or extrapulmonary Microbiologically confirmed	Unknown	C _{max} defined as C _{2hr} sample Normal range 3-6 (daily), 9-18 (biweekly) µg/mL DM not significantly associated with low 2hr H Low H levels – 43% DM, 57% nonDM Normal H levels – 38% DM, 63% nonDM If 2hr H < 3 (0.35-4.70 95% CI 0.71)	NA	NA	Unknown	Unknown	No quantitative C _{max} data available comparing DM and non-DM groups
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116)	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	300	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only Significantly lower in DM group (day 14 median 3.2 µg/mL nonDM, p<0.05, day 30 median 2.9 nonDM versus 3.2 µg/mL, p<0.05)	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	Concentration inversely correlated with weight
Requena-Mendez 2014	Peru	Prospective field PK assessing daily and x2 weekly dosing in DM, HIV and nonDM/HIV groups	25/107 (30 HIV, 52 nonDM/non HIV)	DM significantly older (median 50yrs, versus 29yrs p<0.001)	64% DM male, versus 50% TB group (p0.2)	BMI significantly increased in DM group (median 27 versus 22.9, p<0.001)	2, 6 hrs	1 sampling event from each participant, 57.9% overall in intensive phase, rest in continuation	5mg/kg intensive phase, 15mg/kg continuation phase, up to 800mg	Rest of regimen not specified Daily in intensive phase, x2/week in continuation	72.9% microbiologically confirmed	Known	No significant difference between DM/non-DM in daily or x2 weekly groups (daily group: median 2.6mg/L non-DM, p1, x2/week: median 4.4 DM, x2 nonDM, p0.3)	AUC 0.6 – mg.hr/L No significant difference between DM/non-DM in daily or x2 weekly groups (daily group: median 10.39 DM, 11.05 non-DM, p0.6, x2 weekly: median 54.26 DM, 62.45 nonDM, p0.2)	86.4% total highest concentration at 2hrs in daily group, 90.7 in x2/weekly group. No comment on any differences in DM group	Median random blood glucose 119.5mg/dL	Unknown	Highly variable concentrations in all groups, with >30% not reaching target concentrations.
Hemant Kumar 2016	India	Prospective PK to assess x3 weekly regimen, with DM as one covariate	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	600	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known of random blood glucose >200 µg/mL	No significant difference between DM 11.5 (8.5 – 14.1) versus nonDM 11.5 (8.5 – 14.1) µg/mL	AUC 0.8 µg/ml.hr No significant difference Median DM 37.8 (22.9-53.9) versus nonDM 42.9 (34.2-61.1), p0.08	2hrs for whole group – no analysis comparing DM to nonDM	Unknown	Unknown	DM not significant as a factor on multivariate analysis (C _{max} and AUC)
Kumar 2017	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in Dm group (73.5% versus 65.7, p0.002)	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	600	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 µg/mL (16% new)	C2hr only DM significantly lower Median DM 6 (3.9-10), nonDM 7 (4.6-11.3), p<0.001 DM remains significant independent factor on linear regression	NA	NA	Median random blood glucose 263.5 mg/dL	Majority of diabetes group on treatment	Concentration negatively correlated with blood glucose
Alfarisi 2018	India	Prospective cohort, both PK and PK-PD	101/243	DM significantly older (median age 48 versus 26, p<0.001)	Significantly more men in DM group (77% versus 61%, p<0.001)	Weight significantly increased in DM group (50.8kg versus 45kg, p<0.001)	0.5,2,6hrs	x1 intensive x1 continuation	600	Rifampicin 450 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 3x weekly Rif/Iso alone in continuation (3x weekly)	Pulmonary	Known or HbA1c >6.5%, fasting blood glucose concentration >126 mg/dl, or random blood glucose >200 mg/dl	µg/mL Significantly lower in DM group, not significant after adjustment Intensive: mean DM 5.97, nonDM 7.91, p0.03, adjusted p0.08 Continuation: mean DM 7.42, nonDM 7.63, p0.86	AUC 0.6 µg.hr/ml Significantly lower in DM group, not significant after adjustment Intensive: mean DM 20.0, nonDM 26.84, p0.03, adjusted p0.06 Continuation: mean DM 23.79, nonDM 26.79 p0.45		Median HbA1c at baseline 8.9%	44.6% on metformin	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	300 (>50kg), 225 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radiological/microbiological	Known or fasting glucose >7mmol/L	mg/L Significantly lower in DM group Mean DM 1.6 (0.4-5.8), nonDM 2.8 (1.0-4.6) p0.001	AUC 0.24 mg.h/L Significantly lower in DM group Mean DM 5.4 (0.7-26.9), nonDM 10.6(3.7-22.7), p0.01	No significant difference Median DM 1.0hrs versus 1.1hrs, p0.85	Median HbA1c 111mmol/mol	84% on oral medications	C _{max} /AUC not associated with fasting glucose or HbA1c results DM significantly associated with C _{max} and AUC on multivariate regression
Galvao 2020	Brazil	Prospective PK	26/62	No difference (median 39yrs versus 44)	100%	Weight significantly higher in DM group (Median 64kg versus 54kg)	2hrs	Intensive and Continuation	300	Rifampicin 600 Isoniazid 300 Pyrazinamide 1600 Ethambutol 1100 Daily R/H only in continuation	Pulmonary, clinical, radio, micro	Fasting glucose >126 mg/dl or HbA1c >6.5%	µg/mL C2hr only No significant difference Intensive: Median DM 4.82 (3.47-5.5 IQR) versus nonDM 5.0 (4.1-5.5), p0.43. Continuation: Median DM 3.76 (4.1-5.5) versus nonDM 4.15 (3.82-5.18),			Median HbA1c 9.6%	15% on treatment	No association between concentrations and HbA1c/FBG

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.22.23284586>; this version posted August 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Isoniazid

Ramachandran 2020	India	Prospective PK, specifically looking at association between C _{2hr} and outcomes.	113/404	Median age 40, no breakdown of DM group	64, no breakdown DM group	BMI Median 17.8, no breakdown DM group	2hrs	Intensive and Continuation	600	R 450/600 H 600 Z 1500 E 1200 3x weekly CP: R/H	Pulmonary	Known or HbA1c >6.5%, or RBG >200 mg/dl	p0.38 µg/mL C _{2hr} No significant difference Mth 1: 7.34 (2.68-8.28) Mth 5: 5.17-7.89 v 6.63 (3.49-9.09), p0.10	NA	NA	Unknown	Unknown	
-------------------	-------	--------------------------------------------------------------------------------------------	---------	-----------------------------------------	---------------------------	----------------------------------------	------	----------------------------	-----	----------------------------------------------------------------	-----------	-----------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------	----	----	---------	---------	--

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.29.23294656>; this version posted August 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Ethambutol

Study	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C _{max}	AUC	T _{max} (Hrs)	DM Control	DM Treatment	Other PK
Ruslami 2010	Indonesia	Prospective	17/34	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0.00	Matched (42% male)	Matched (within 5kg) (mean 47.3kg both groups)	Intensive	Intensive	750	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg	Pulmonary	Known (60%) Screening via WHO criteria (40%)	mg/L No difference Mean 2.2 (1.95-2.4) DM 1.95 (1.6-2.4) nonDM p0.3	0-24 mg x h/L No difference Mean 13.8 (12.0-15.9) DM v 13.5 (12.0-15.1) nonDM p0.77	No difference Median 3 (1-4 range) DM v 3 (1-6) nonDM p0.93	Mean HbA1c 11.1% Median FBG 16.6mmol/L	None	No correlation between FBG and AUC/C _{max} 10 DM cases treated with insulin to achieve glycaemic control, with PK repeated 6 weeks later – non significant change in AUC/other PK
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116)	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	1000	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only No significant difference between DM and nonDM, p>0.05, mean 2.8 versus 3.6 mg/L (p>0.05)	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55kg non, p0.258)	Intensive	Intensive	1100 (>50kg), 825 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radiological/microbiological	Known or fasting glucose >7mmol/L	mg/L No significant difference Mean DM 3.3 (2.2-5.0) versus 3.3 (2.2-5.0) nonDM p0.67	AUC0-24 mg.h/L No significant difference Mean DM 19.6 (7.5-40.4), nonDM 20.2 (13.4-32.0), p0.78	No significant difference Median DM 2.0hrs versus 2.0hrs, p0.31	Median HbA1c 11.1mmol/mol	84% on oral medications	C _{max} /AUC not associated with fasting glucose or HbA1c results

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.29.23294556>; this version posted August 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Other

Study	Agent	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C _{max}	AUC	DM Control	DM Treatment	Other PK
Zhu 2018	Cycloserine	China	Retrospective – all cases receiving TDM last 4 years, DM a covariant	19/200	Mean 35.8, no b/down DM group	63% male, no breakdown Dm group	Mean BMI 21.3, no b/down DM group	2hr	Unknown	500 <50kg 750 >50kg	Unknown	Unknown	Known	NA	NA	Unknown	Unknown	Normal range 20-35 µg/ml No significant difference in % DM with low concentrations DM 68% low v nonDM 60% low (p0.427)
Zhu 2018	Linezolid	China	Retrospective – all cases receiving TDM last 4 years, DM a covariant	6/65	Mean 34.7, no b/down DM group	52% male, no b/down DM group	Mean BMI 21.2, no b/down DM group	2hr	Unknown	600	Unknown	Unknown	Known	NA	NA	Unknown	Unknown	Normal range 12-26 µg/ml No significant difference in % DM with low concentrations DM 17% low v nonDM 21% low (p1.00)
Dekkers 2019	Moxifloxacin	The Netherlands	Retrospective – all DM cases receiving moxi TDM over 12 yrs with matched controls	16/32	Matched Median 52 (DM) v 49 (nonDM)	Matched 69% male (DM) v 63% male (nonDM)	BMI - No signif difference 21.9 (DM) v 20.7 (nonDM)	Varied, median 6-7 samples	Intensive	6.5-6.6mg/kg	Varied	50% pTB (DM), 75% pTB (nonDM) 31% MDR (DM), 38% MDR (nonDM)	Known	Mg/L Significantly lower in DM Median DM 1.7 (IQR 1.3-2.6) v nonDM 2.4 (2.0-3.0), p<0.05	0-24 mg.hr/L Significantly lower in DM Median DM 17.4 (IQR 12.5-21.8) v nonDM 23.2 (16.8-32.1), p<0.05	Median HbA1c 8.3% (only in 9 patients)	14/16 receiving insulin	Clearance increased in DM group No difference in Tlag/ka

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.29.23294556>; this version posted August 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.